Business — Page 6
Page 6 of the Business archive on FinancialMarkets.com.
Latest articles
- Tesla Delivered 22,000 More Cars Than It Built and Beat Estimates by 24,000. Its Energy Business Missed by 14%.
- Tesla's Delivery Number Lands on Jobs Day, With 462,000 the Bar to Clear
- Nike's Dividend Now Costs More Than the Company Expects to Earn
- Nike Beats on Quarterly Profit, Then Guides a Quarter Below Wall Street for the Year
- Vicor Raised Its Growth Forecast to More Than 30% From More Than 20%. Its Shares Opened 14% Higher and Gave Back About a Third of the Gain.
- Nike Shares Started the Year Near $64. They Go Into Tonight's Report at About $36.
- McCormick Beat Profit Forecasts by 10 Cents a Share. Its Shares Fell About 2%, in Step With Its Acquirer Unilever.
- Micron's Revenue Nearly Quintupled in a Year. Its Stock Moved About 1%, a Fraction of What Options Had Priced.
- Accenture Grew 7% in Local Currency Last Quarter and Guided Next Year to 3% to 6%. The Stock Jumped About 17%.
- Earnings Test Consumer and Corporate Spending
- MongoDB Raises Targets and Adds $1B Buyback
- Micron Revenue Surges as Margin Outlook Softens
- CarMax Sold 13.8% More Used Cars Last Quarter. It Made $111 Less on Each One.
- FactSet Posted Record Subscription Growth and Set Next Year's Range Below It. Shares Rose About 3%.
- Conagra Beat Profit Forecasts by 10 Cents a Share. Cash From Its Operations Turned Negative.
- Jabil Beat Revenue Forecasts by About $900 Million and Raised Its Outlook. The Stock Fell About 10%.
- MongoDB Expands Buyback to $2 Billion After CEO Departure
- Micron Faces Revenue Expectations Above Its Guidance
- AMD Agrees to Acquire World Labs in $8.2 Billion Stock Deal
- Getty Images Nears Interest-Payment Deadline Without Announced Financing
- Paramount–Warner Deal Faces Deadline as Delay Fees Near
- Micron Reports Wednesday With Earnings Expected to Rise About Tenfold. The Stock Trades at 6.5 Times Forward Profit.
- Carnival Raised Its Full-Year Outlook Above Wall Street's. Its Fourth-Quarter Forecast Came In Below It.
- Kodiak's Eye Drug Hits Its Mark, and Half of Patients Went Six Months Between Shots